JP2021512051A5 - - Google Patents

Info

Publication number
JP2021512051A5
JP2021512051A5 JP2020537529A JP2020537529A JP2021512051A5 JP 2021512051 A5 JP2021512051 A5 JP 2021512051A5 JP 2020537529 A JP2020537529 A JP 2020537529A JP 2020537529 A JP2020537529 A JP 2020537529A JP 2021512051 A5 JP2021512051 A5 JP 2021512051A5
Authority
JP
Japan
Prior art keywords
inhibitors
receptor
modifiers
pharmaceutical composition
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020537529A
Other languages
English (en)
Japanese (ja)
Other versions
JP7862931B2 (ja
JP2021512051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014720 external-priority patent/WO2019147650A1/en
Publication of JP2021512051A publication Critical patent/JP2021512051A/ja
Publication of JP2021512051A5 publication Critical patent/JP2021512051A5/ja
Priority to JP2023146956A priority Critical patent/JP2023182599A/ja
Priority to JP2025036312A priority patent/JP2025093997A/ja
Application granted granted Critical
Publication of JP7862931B2 publication Critical patent/JP7862931B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020537529A 2018-01-23 2019-01-23 ペプチドｙｙ薬学的調剤物、組成物、および方法 Active JP7862931B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023146956A JP2023182599A (ja) 2018-01-23 2023-09-11 ペプチドｙｙ薬学的調剤物、組成物、および方法
JP2025036312A JP2025093997A (ja) 2018-01-23 2025-03-07 ペプチドｙｙ薬学的調剤物、組成物、および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862620580P 2018-01-23 2018-01-23
US62/620,580 2018-01-23
US201862669191P 2018-05-09 2018-05-09
US62/669,191 2018-05-09
PCT/US2019/014720 WO2019147650A1 (en) 2018-01-23 2019-01-23 Peptide yy pharmaceutical formulations, compositions, and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146956A Division JP2023182599A (ja) 2018-01-23 2023-09-11 ペプチドｙｙ薬学的調剤物、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2021512051A JP2021512051A (ja) 2021-05-13
JP2021512051A5 true JP2021512051A5 (enExample) 2022-01-27
JP7862931B2 JP7862931B2 (ja) 2026-05-20

Family

ID=67391725

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020537529A Active JP7862931B2 (ja) 2018-01-23 2019-01-23 ペプチドｙｙ薬学的調剤物、組成物、および方法
JP2023146956A Pending JP2023182599A (ja) 2018-01-23 2023-09-11 ペプチドｙｙ薬学的調剤物、組成物、および方法
JP2025036312A Pending JP2025093997A (ja) 2018-01-23 2025-03-07 ペプチドｙｙ薬学的調剤物、組成物、および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023146956A Pending JP2023182599A (ja) 2018-01-23 2023-09-11 ペプチドｙｙ薬学的調剤物、組成物、および方法
JP2025036312A Pending JP2025093997A (ja) 2018-01-23 2025-03-07 ペプチドｙｙ薬学的調剤物、組成物、および方法

Country Status (11)

Country Link
US (4) US11911445B2 (enExample)
EP (1) EP3743092A4 (enExample)
JP (3) JP7862931B2 (enExample)
KR (1) KR20200132852A (enExample)
CN (1) CN112074286A (enExample)
AU (2) AU2019211322A1 (enExample)
BR (1) BR112020014596A2 (enExample)
CA (1) CA3087733A1 (enExample)
IL (1) IL276169A (enExample)
MX (1) MX2020007410A (enExample)
WO (1) WO2019147650A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492505B2 (en) 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods
RS64265B1 (sr) * 2018-12-21 2023-07-31 Univ Strasbourg Peptidi za lečenje i prevenciju dijabetesa i povezanih poremećaja
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
KR20220100925A (ko) 2019-11-11 2022-07-18 베링거 인겔하임 인터내셔날 게엠베하 Npy2 수용체 작용제
MX2022009136A (es) * 2020-02-13 2022-08-22 Ferrer Int Composicion farmaceutica oftalmica y uso de la misma.
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2022224061A1 (en) * 2021-04-21 2022-10-27 Societe Des Produits Nestle Sa Methods of identifying modulators of receptors over-expressed in circumvallate taste papillae in animals such as cats, methods of using such modulators in food, and foods made by such methods
JP2024516834A (ja) * 2021-04-30 2024-04-17 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Ｏｘｍ３保存剤、ｏｘｍ３製剤および調製方法
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN114306207A (zh) * 2021-12-30 2022-04-12 电子科技大学 一种以棒棒糖为载体的口腔给药方法
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
US12171880B2 (en) * 2022-09-08 2024-12-24 Taiwan Mercury Medical Corporation Metformin tablet for relieving pain and reducing inflammation and manufacturing method thereof
DE102024102935A1 (de) * 2024-02-01 2025-08-07 Briu Gmbh Schmelztablette, insbesondere zur Verwendung als Nahrungsergänzungsmittel
WO2025208093A1 (en) * 2024-03-28 2025-10-02 Gila Therapeutics, Inc. Compositions and methods for treating metabolic diseases with topical-lingual receptor agonists
ES3074253A1 (es) * 2025-01-20 2026-07-20 Palefiber Sl Espray bucal sublingual para reducir el peso de un consumidor
ES3074379A1 (es) * 2025-01-20 2026-07-20 Palefiber Sl Espray bucal sublingual para la diabetes tipo 2

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
US7208186B2 (en) 2001-09-18 2007-04-24 Spi Pharma, Inc. Chewing gum formulation and method of making the same
ES2320979T3 (es) * 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4733922B2 (ja) * 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US20150283213A1 (en) 2002-08-01 2015-10-08 Mannkind Corporation Method for treating hyperglycemia with glp-1
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
MXPA05012278A (es) 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.
US20070149451A1 (en) 2003-11-17 2007-06-28 Holmes David G Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
ES2393324T3 (es) 2004-05-14 2012-12-20 Emisphere Technologies, Inc. Compuestos y composiciones para administrar principios activos
US20080125360A1 (en) 2004-05-18 2008-05-29 Henrik Nilsson Composition Comprising Pyy for the Treatment of Gastrointestinal Disorders
JP2007538017A (ja) 2004-05-18 2007-12-27 アディテック・ファルマ・アクチボラゲット 胃腸疾患の治療のためのｐｐｙ含有組成物
WO2006007412A2 (en) * 2004-06-16 2006-01-19 Nastech Pharmaceutical Company Inc. Peptide yy formulations having increased stability and resistance to microbial agents
CN105708787A (zh) 2004-07-12 2016-06-29 爱密斯菲尔科技公司 用于递送肽yy和pyy激动剂的组合物
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20080064632A1 (en) 2004-09-24 2008-03-13 Amatruda John M Combination Therapy for the Treatment of Obesity
US8283312B2 (en) 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2007008778A2 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
US20070104763A1 (en) 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
AU2007281433A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
MX2009006699A (es) * 2006-12-21 2009-06-30 Mallinckrodt Inc Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
AU2008223431B2 (en) 2007-03-05 2013-06-13 Syracuse University A conjugate of insulin and vitamin B12 for oral delivery
ES2359875T3 (es) 2007-05-01 2011-05-27 Cephalon, Inc. Composición para suministro transmucosal de polipéptidos.
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2009153634A1 (en) * 2008-06-19 2009-12-23 University Of Witwatersrand, Johannesburg A transmucosal delivery system
US9492505B2 (en) 2009-01-21 2016-11-15 University Of Florida Research Foundation, Inc. Satiation peptide administration
WO2010092163A2 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
EP4286400A3 (en) 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2016513712A (ja) 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
EP2968439A2 (en) * 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
EP3113764B1 (en) * 2014-03-04 2020-07-22 Eastgate Pharmaceuticals Inc. Pharmaceutical composition for transmucosal delivery and methods for treating diabetes in a subject in need thereof
WO2015177572A1 (en) 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US11311633B2 (en) 2016-04-16 2022-04-26 University Of Florida Research Foundation, Incorporated Satiation peptides for weight loss and altered taste sensitivity
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN107778336B (zh) 2016-08-24 2022-09-27 宜昌东阳光长江药业股份有限公司 吡喃葡萄糖基衍生物的结晶形式
MX2020007167A (es) * 2018-01-09 2020-11-06 Gila Therapeutics Inc Composiciones y metodos para tratar enfermedades metabolicas.
US11911445B2 (en) 2018-01-23 2024-02-27 Gila Therapeutics, Inc. Peptide YY pharmaceutical formulations, compositions, and methods

Similar Documents

Publication Publication Date Title
US11382957B2 (en) Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2020202573B2 (en) Use of long-acting GLP-1 peptides
JP5918539B2 (ja) Ｇｌｐ−１を用いる高血糖症の治療方法
ES2547529T3 (es) Formulación en polvo seco inhalable que comprende GLP-1 para usar en el tratamiento de la hiperglucemia y diabetes por administración pulmonar
US8921311B2 (en) Method for treating hyperglycemia
TWI623320B (zh) 用於治療代謝症候群之醫藥組成物
US20150283213A1 (en) Method for treating hyperglycemia with glp-1
Jones et al. Islet function and insulin secretion
JP2015526523A (ja) 高血糖症の治療のための方法および組成物
JP2019524831A5 (enExample)
JP2018501276A5 (enExample)
US20060063719A1 (en) Methods for treating diabetes
Holst Incretin therapy for diabetes mellitus type 2
US11304992B2 (en) Inhalable dry powder pharmaceutical composition
JP2024509829A (ja) Ｇｌｐ－１受容体作動薬を経口投与するための医薬組成物
Ghosh et al. Chapter-6 Role of Pancreastatin Inhibitor (s) in ROS Induced Insulin Resistance
Abhay et al. Pharmacotherapy Of Type 2 Diabetes–The Future
Ghosh et al. Role of Proteases in Diabetes Mellitus
Erol Neural pathways and neuropeptides mediate the therapeutic actions of DPP IV inhibitors in type-2 diabetes